Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage

Hayden Zaccagni, Justin Fried, John Cornell, Patricia Padilla, Robin L Brey

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Nervous system dysfunction may occur in as many as 80% of patients with Systemic Lupus Erythematous (SLE) at some point in their disease course. Upregulation of adhesion molecules has been linked to acute SLE-related disease activity and chronic damage. We evaluated the relationship between soluble adhesion molecule levels and neuropsychiatric lupus (NPSLE) manifestations using the American College of Rheumatology (ACR) case definitions to investigate for evidence of a link between upregulation of adhesion molecules and NPSLE manifestations. Sera from the initial study visit of 133 SLE patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) and 40 controls were evaluated for soluble adhesion molecule levels (VCAM-1, ICAM-1 and E-selectin) and antiphospholipid antibodies. A subset of 57 SLE patients were evaluated for soluble adhesion molecule levels and antiphospholipid antibodies on two subsequent study visits, as well. NPSLE manifestations at the time of sera ascertainment were recorded using ACR case definitions and SLE-related acute activity and damage were measured. Elevated levels of all three soluble adhesion molecules were seen in SLE patients compared to normal control values. Soluble VCAM-1 levels correlated with measures of current disease activity, NPSLE manifestations and deep venous thrombosis. Persistently positive levels of ICAM-1 and VCAM-1, but not E-selectin were association with increased SLE-related damage. Elevated levels of all soluble adhesion molecule levels correlated with abnormal levels of antiphospholipid antibodies, which are associated with some NPSLE manifestations and have been shown to upregulate adhesion molecule expression.

Original languageEnglish (US)
Pages (from-to)1654-1659
Number of pages6
JournalFrontiers in Bioscience
Volume9
StatePublished - 2004

Fingerprint

Antiphospholipid Antibodies
Vascular Cell Adhesion Molecule-1
Adhesion
Molecules
E-Selectin
Up-Regulation
Intercellular Adhesion Molecule-1
Rheumatology
Serum
Venous Thrombosis
Nervous System
Reference Values
Chronic Disease
Neurology

Keywords

  • Adhesion Molecules
  • Neuropsychiatric Disease
  • Systemic Lupus Erythematosus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. / Zaccagni, Hayden; Fried, Justin; Cornell, John; Padilla, Patricia; Brey, Robin L.

In: Frontiers in Bioscience, Vol. 9, 2004, p. 1654-1659.

Research output: Contribution to journalArticle

Zaccagni, H, Fried, J, Cornell, J, Padilla, P & Brey, RL 2004, 'Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage', Frontiers in Bioscience, vol. 9, pp. 1654-1659.
Zaccagni, Hayden ; Fried, Justin ; Cornell, John ; Padilla, Patricia ; Brey, Robin L. / Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage. In: Frontiers in Bioscience. 2004 ; Vol. 9. pp. 1654-1659.
@article{8d9879307468406abd2ebdd401349036,
title = "Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage",
abstract = "Nervous system dysfunction may occur in as many as 80{\%} of patients with Systemic Lupus Erythematous (SLE) at some point in their disease course. Upregulation of adhesion molecules has been linked to acute SLE-related disease activity and chronic damage. We evaluated the relationship between soluble adhesion molecule levels and neuropsychiatric lupus (NPSLE) manifestations using the American College of Rheumatology (ACR) case definitions to investigate for evidence of a link between upregulation of adhesion molecules and NPSLE manifestations. Sera from the initial study visit of 133 SLE patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) and 40 controls were evaluated for soluble adhesion molecule levels (VCAM-1, ICAM-1 and E-selectin) and antiphospholipid antibodies. A subset of 57 SLE patients were evaluated for soluble adhesion molecule levels and antiphospholipid antibodies on two subsequent study visits, as well. NPSLE manifestations at the time of sera ascertainment were recorded using ACR case definitions and SLE-related acute activity and damage were measured. Elevated levels of all three soluble adhesion molecules were seen in SLE patients compared to normal control values. Soluble VCAM-1 levels correlated with measures of current disease activity, NPSLE manifestations and deep venous thrombosis. Persistently positive levels of ICAM-1 and VCAM-1, but not E-selectin were association with increased SLE-related damage. Elevated levels of all soluble adhesion molecule levels correlated with abnormal levels of antiphospholipid antibodies, which are associated with some NPSLE manifestations and have been shown to upregulate adhesion molecule expression.",
keywords = "Adhesion Molecules, Neuropsychiatric Disease, Systemic Lupus Erythematosus",
author = "Hayden Zaccagni and Justin Fried and John Cornell and Patricia Padilla and Brey, {Robin L}",
year = "2004",
language = "English (US)",
volume = "9",
pages = "1654--1659",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Soluble adhesion molecule levels, neuropsychiatric lupus and lupus-related damage

AU - Zaccagni, Hayden

AU - Fried, Justin

AU - Cornell, John

AU - Padilla, Patricia

AU - Brey, Robin L

PY - 2004

Y1 - 2004

N2 - Nervous system dysfunction may occur in as many as 80% of patients with Systemic Lupus Erythematous (SLE) at some point in their disease course. Upregulation of adhesion molecules has been linked to acute SLE-related disease activity and chronic damage. We evaluated the relationship between soluble adhesion molecule levels and neuropsychiatric lupus (NPSLE) manifestations using the American College of Rheumatology (ACR) case definitions to investigate for evidence of a link between upregulation of adhesion molecules and NPSLE manifestations. Sera from the initial study visit of 133 SLE patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) and 40 controls were evaluated for soluble adhesion molecule levels (VCAM-1, ICAM-1 and E-selectin) and antiphospholipid antibodies. A subset of 57 SLE patients were evaluated for soluble adhesion molecule levels and antiphospholipid antibodies on two subsequent study visits, as well. NPSLE manifestations at the time of sera ascertainment were recorded using ACR case definitions and SLE-related acute activity and damage were measured. Elevated levels of all three soluble adhesion molecules were seen in SLE patients compared to normal control values. Soluble VCAM-1 levels correlated with measures of current disease activity, NPSLE manifestations and deep venous thrombosis. Persistently positive levels of ICAM-1 and VCAM-1, but not E-selectin were association with increased SLE-related damage. Elevated levels of all soluble adhesion molecule levels correlated with abnormal levels of antiphospholipid antibodies, which are associated with some NPSLE manifestations and have been shown to upregulate adhesion molecule expression.

AB - Nervous system dysfunction may occur in as many as 80% of patients with Systemic Lupus Erythematous (SLE) at some point in their disease course. Upregulation of adhesion molecules has been linked to acute SLE-related disease activity and chronic damage. We evaluated the relationship between soluble adhesion molecule levels and neuropsychiatric lupus (NPSLE) manifestations using the American College of Rheumatology (ACR) case definitions to investigate for evidence of a link between upregulation of adhesion molecules and NPSLE manifestations. Sera from the initial study visit of 133 SLE patients enrolled in the San Antonio Lupus Study of Neuropsychiatric Disease (SALUD) and 40 controls were evaluated for soluble adhesion molecule levels (VCAM-1, ICAM-1 and E-selectin) and antiphospholipid antibodies. A subset of 57 SLE patients were evaluated for soluble adhesion molecule levels and antiphospholipid antibodies on two subsequent study visits, as well. NPSLE manifestations at the time of sera ascertainment were recorded using ACR case definitions and SLE-related acute activity and damage were measured. Elevated levels of all three soluble adhesion molecules were seen in SLE patients compared to normal control values. Soluble VCAM-1 levels correlated with measures of current disease activity, NPSLE manifestations and deep venous thrombosis. Persistently positive levels of ICAM-1 and VCAM-1, but not E-selectin were association with increased SLE-related damage. Elevated levels of all soluble adhesion molecule levels correlated with abnormal levels of antiphospholipid antibodies, which are associated with some NPSLE manifestations and have been shown to upregulate adhesion molecule expression.

KW - Adhesion Molecules

KW - Neuropsychiatric Disease

KW - Systemic Lupus Erythematosus

UR - http://www.scopus.com/inward/record.url?scp=2442715490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442715490&partnerID=8YFLogxK

M3 - Article

C2 - 14977576

AN - SCOPUS:2442715490

VL - 9

SP - 1654

EP - 1659

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -